Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-pVAX1
- Development stage
- Phase 1
- Lead developer
- Karolinska Institutet
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
N-pVAX1 is an investigational DNA vaccine designed to protect against Crimean Congo Hemorrhagic Fever (CCHF). It is being evaluated in a first-in-human, dose-escalation phase I clinical trial for its safety, reactogenicity, and immunogenicity. The vaccine is delivered via in vivo electroporation (EP) as three intramuscular doses at weeks 0, 4, and 12. The primary goal of the study is to assess safety and immune response by measuring antibody levels against the CCHF nucleocapsid protein. Secondary objectives include detailed analysis of both humoral and cellular immune responses[2][3][4].
- Brand names
- N-pVAX1N-pVAX-1N-pVAX 1
- Other names
- N-pVAX1N-pVAX-1N-pVAX 1
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on N-pVAX1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-pVAX1.